home / stock / adma / adma news

ADMA News and Press, ADMA Biologics Inc From 10/19/23

Stock Information
Company Name: ADMA Biologics Inc
Stock Symbol: ADMA
Market: NASDAQ
Website: admabiologics.com
Menu
ADMA ADMA Quote ADMA Short ADMA News ADMA Articles ADMA Message Board
Get ADMA Alerts

News, Short Squeeze, Breakout and More Instantly...
ADMA - ADMA, RVNC and BMEA are among after hour movers

2023-10-19 17:11:44 ET Gainers: PacWest Bancorp ( PACW ) +7% . Biomea Fusion ( BMEA ) +5% . Bank OZK ( OZK ) +3% . ADMA Biologics ( ADMA ) +3% . Revance Therapeutics ( RVNC ) +3% . Losers: SolarEdge Technologies ( SEDG ...
ADMA - ADMA, ALLK and NRIX are among after hour movers

2023-09-11 17:20:07 ET Gainers: Matrix Service  ( MTRX ) +10% . Adeia  ( ADEA ) +7% . Allakos  ( ALLK ) +5% . Nurix Therapeutics ( NRIX ) +5% . ADMA Biologics ( ADMA ) +4% . Losers: ACELYRIN ( SLRN ) ...

ADMA - Why Shares of ADMA Biologics Are Climbing Thursday

2023-08-10 14:31:53 ET Shares of ADMA Biologics (NASDAQ: ADMA) were up more than 12% as of 2 p.m. ET on Thursday. The healthcare company reported second-quarter earnings on Wednesday, after the markets closed. The stock is up more than 17% this year and reached a 52-week high on...

ADMA - ADMA Biologics, Inc. (ADMA) Q2 2023 Earnings Call Transcript

2023-08-09 20:52:03 ET ADMA Biologics, Inc. (ADMA) Q2 2023 Earnings Conference Call August 09, 2023, 16:30 ET Company Participants Skyler Bloom - Senior Director, Business Development & Corporate Strategy Adam Grossman - Co-Founder, President, CEO & Director ...
ADMA - ADMA Biologics GAAP EPS of -$0.03 in-line, revenue of $60.13M beats by $4.63M

2023-08-09 16:20:32 ET ADMA Biologics press release ( NASDAQ: ADMA ): Q2 GAAP EPS of -$0.03 in-line. Revenue of $60.13M (+77.4% Y/Y) beats by $4.63M . FY2024 and 2025 Total Revenue Guidance Increased to $275 Million vs $226.03M consensus and $325 Million or Mo...

ADMA - ADMA Biologics Announces Second Quarter 2023 Financial Results and Provides Business Update

2Q2023 Total Revenues of $60.1 Million, a 77% Y-o-Y Increase 2Q2023 Adjusted EBITDA (1) of $6.4 Million, a 160% Q-o-Q Improvement 2Q2023 Adjusted Net Loss (2) of $3.6 Million, a 74% Y-o-Y Improvement FY2023 Total Revenue Now Expected to Ex...

ADMA - ADMA Biologics to Report Second Quarter 2023 Financial Results on August 9, 2023

RAMSEY, N.J. and BOCA RATON, Fla., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologi...
ADMA - ADMA BioCenters Receives FDA Approval for its Ninth Plasma Collection Center, Located in Dallas, GA

FDA Approval Supports Corporate Goal of Plasma Supply Self-Sufficiency and Ongoing Revenue Growth Company Remains On-Track to Have All 10 Plasma Collection Centers FDA-Licensed by Year-End 2023 RAMSEY, N.J. and BOCA RATON, Fla. and DALLAS, Ga., July 19, 2023 (GLOBE NEWSWIRE) -- AD...

ADMA - ADMA Biologics: Adding Intrinsic Value Based On The Catalysts

2023-06-15 22:10:33 ET Summary ADMA continues its demonstrated sales performance with another tremendous growth in revenue for Q1 last month. There are fundamental, sentimental and valuation facts to suggest ADMA is mispriced in my opinion. Reiterate buy, seeking a 20% return ...

ADMA - ADMA Biologics, Inc. (ADMA) Q1 2023 Earnings Call Transcript

2023-05-10 21:02:04 ET ADMA Biologics, Inc. (ADMA) Q1 2023 Results Conference Call May 10, 2023 04:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and Chief Executive Officer Bria...
Previous 10 Next 10